Table 1 Improved tumor control with concurrent chemo-radiotherapy

From: Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies

Cancer

Chemotherapy given with RT

Patient outcomes

Targetable receptor

FDA approved ADC

GBM

Temozolomide

2 yr OS22: RT 10.9% CRT 27.2%

  

Head and Neck

Cisplatin, carboplatin, 5-FU

3 yr OS3: RT 31% CRT 51%

TF

TV

Esophageal

Cisplatin, carboplatin, 5-FU, paclitaxel

5 yr OS4: RT 0% CRT 26%

HER2

T-DXd, T-DM1

NSCLC

Cisplatin, carboplatin, vinblastine, paclitaxel, etoposide

5 yr OS5: sequential CRT 10% concurrent CRT 16%

HER2 TF

T-DXd, T-DM1, TV

Rectal

5-FU, capecitabine

5 yr LF6: RT 16.5% CRT 8.1%

HER2 TF

T-DXd, T-DM1, TV

Anal

MMC, 5-FU

LF7: RT 59% CRT 36%

  

Bladder

Cisplatin, MMC, 5-FU

2 yr DFS8: RT 54% CRT 67%

Nectin-4 Trop-2

EV, SG

Cervical

Cisplatin, 5-FU

5 yr OS9: RT 58% CRT 73%

TF

TV

  1. 5-FU 5-Fluorouracil, LF Local failure, T-DM1 Trastuzumab emtansine, ADC Antibody drug conjugate, MMC Mitomycin C, T-DXd Trastuzumab deruxtecan, CRT Chemo-radiotherapy, NSCLC Non-small cell lung cancer, TF Tissue factor, DFS Disease free survival, OS Overall survival, Trop-2 Trophoblast antigen 2, EV Enfortumab vedotin, RT Radiotherapy, TV Tisotumab vedotin, GBM Glioblastoma, SG Sacituzumab govitecan.
Back to article page